Major Depressive Disorder Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers

How Will the Major Depressive Disorder Market Grow, and What Is the Projected Market Size?
The major depressive disorder market has seen steady growth in recent years. It will increase from $6.12 billion in 2024 to $6.28 billion in 2025, at a CAGR of 2.6%. This growth can be attributed to advances in pharmaceuticals, increased mental health awareness, psychological therapies, and public health initiatives.

The Major Depressive Disorder market will grow to $7.13 billion by 2029, at a CAGR of 3.2%, driven by precision medicine, telepsychiatry, novel treatments, and mental health service expansion. Key trends include early intervention, peer support, holistic approaches, and resilience-building strategies.

What Key Elements Are Boosting Growth in the Major Depressive Disorder Market?
The rise in substance and alcohol abuse is expected to accelerate the growth of the major depressive disorder (MDD) market. These forms of abuse often occur alongside MDD and exacerbate its effects, increasing both physical and psychological harm. According to a July 2024 survey from the Substance Abuse and Mental Health Services Administration, 3.1% of the population misused opioids in 2023, while 21.8% of individuals aged 12 or older used marijuana. The increase in substance and alcohol abuse is contributing to the growing demand for treatments in the MDD market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13042&type=smp

Who Are the Major Industry Players Fueling Major Depressive Disorder Market Expansion?
Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research And Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co.Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon PLC, Allergan PLC, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BioLite Inc., BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Arrivo Bioventures LLC, Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

What Are the Emerging Trends in the Major Depressive Disorder Industry?
In the major depressive disorder market, companies are focusing on developing innovative treatments and gaining regulatory approval to enhance their competitive edge. With increasing drug approvals for treatments like VRAYLAR (cariprazine), the market is seeing more effective and safer options. For instance, in December 2022, AbbVie Inc., a US-based pharmaceutical company, received FDA approval for VRAYLAR (cariprazine) as an adjunctive therapy for major depressive disorder in adults. VRAYLAR is the first atypical antipsychotic medication approved to be used alongside antidepressants for MDD and is taken once daily in capsule form.

How Is the Segmentation of the Major Depressive Disorder Market Defined?
The major depressive disorder market covered in this report is segmented -

1) By Treatment: Psychotherapy, Medications, Electroconvulsive Therapy (ECT), Transcranial Magnetic Stimulation (TMS), Other Treatments
2) By Diagnosis: Physical Examinations, Laboratory Tests, Psychiatric Evaluations, Diagnostic And Statistical Manual of Mental Disorders (DSM-5), Other Diagnosis
3) By End-User: Clinics, Hospitals, Other End-Users

Subsegments:
1) By Psychotherapy: Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT), Dialectical Behavior Therapy (DBT), Psychodynamic Therapy
2) By Medications: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants (TCAs), Monoamine Oxidase Inhibitors (MAOIs), Atypical Antidepressants
3) Electroconvulsive Therapy (ECT): Unilateral ECT, Bilateral ECT, Modified ECT
4) Transcranial Magnetic Stimulation (TMS): Repetitive Transcranial Magnetic Stimulation (rTMS), Deep Transcranial Magnetic Stimulation (dTMS), Theta Burst Stimulation (TBS), Navigated Brain Stimulation (nTMS)
5) Other: Cognitive Behavioral Therapy (CBT), Psychodynamic Therapy, Interpersonal Therapy (IPT), Vagus Nerve Stimulation (VNS), Ketamine Therapy, Bright Light Therapy, Psychedelic-Assisted Therapy, Medication (Antidepressants)

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/major-depressive-disorder-global-market-report

What Is the Leading Region in the Major Depressive Disorder Market?
North America was the largest region in the major depressive disorder market in 2024. The regions covered in major depressive disorder market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Major Depressive Disorder Global Market Report?

- Market Size Analysis: Analyze the Major Depressive Disorder Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Major Depressive Disorder Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Major Depressive Disorder Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Major Depressive Disorder Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.